Background
==========

Endogenous erythropoietin production is greatly reduced for patients receiving maintenance hemodialysis, who generally require regular administration of exogenous erythropoietin or transfusions. A subset of these patients receive very large doses of erythropoiesis-stimulating agents (ESAs) as part of a strategy for anemia management. The term "ESA hyporesponsive" has been used to refer to patients who need high doses of ESAs to increase and maintain their hemoglobin levels. This phenomenon is generally believed to be due to a variety of factors, including absolute or functional iron deficiency and inflammation. Patients can experience short-term acute episodes of hyporesponsiveness, or longer more chronic episodes. There does not appear to be a standardized definition of ESA hyporesponsiveness. However, a number of studies have investigated various aspects of hyporesponsiveness, using a variety of definitions and producing different estimates of proportions of hyporesponsive patients and factors associated with hyporesponsiveness. Management of anemia is expensive for these patients, and interest in increasing treatment effectiveness and efficiency is growing, particularly with the January 2011 implementation of the new Medicare dialysis reimbursement bundle, which includes ESAs. In this study, we sought to investigate different definitions of ESA hyporesponsiveness and their associations with patient characteristics. We applied three different definitions of hyporesponsiveness to the same large, national cohort of hemodialysis patients to assess the impact of definition on counts and on patient characteristics associated with hyporesponsiveness.

Methods
=======

Subjects and measurements
-------------------------

We studied point prevalent in-center and home hemodialysis patients on May 1, 2008, with Medicare as primary payer, who survived through December 31, 2008. Included patients received recombinant human erythropoietin (EPO) in each month, August through December. Figure [1](#F1){ref-type="fig"} displays the time periods used in the study. The months August through December were used to characterize hyporesponsiveness and comorbidity concurrent with the hyporesponsiveness period. The months May through July were used to characterize comorbidity prior to the hyporesponsive period (antecedent period).

![**Study time periods.**The months August through December were used to characterize hyporesponsiveness and comorbidity concurrent with the hyporesponsiveness period. The months May through July were used to characterize comorbidity prior to the hyporesponsive period (antecedent period).](1471-2369-14-44-1){#F1}

Three different definitions of hyporesponsiveness were applied to each of the 5 months:

1\. Above the ninetieth percentile of total monthly EPO dose.

2\. Above the ninetieth percentile of total monthly EPO dose divided by patient weight in kg.

3\. Above the ninetieth percentile of total monthly EPO dose divided by patient hemoglobin level (also known as the EPO resistance index).

Definition 2 acknowledges that EPO dosing may depend on patient weight, and definition 3 considers a measure that has been used in other studies to assess issues related to hyporesponsiveness. Table [1](#T1){ref-type="table"} displays the distributions for these definitions. As an example, using total monthly EPO dose, a patient whose total dose was greater than 176,400 units (the ninetieth percentile) was considered hyporesponsive for that month. Each patient in the hyporesponsive category for at least 1 of the 5 months was considered hyporesponsive. Next, considering all 5 months for each patient, hyporesponsive patients were further classified as chronic (hyporesponsive in ≥ 4 consecutive months), acute (hyporesponsive in ≤ 3 consecutive months and not hyporesponsive for at least 1 month before and 1 month after the hyporesponsive months), or other (neither the chronic nor the acute definition applied).

###### 

**Distributions of hyporesponsiveness definitions**^**\***^

                                                   **Percentile**                                                
  --------------------------------------- ------- ---------------- ---------- ---------- ----------- ----------- -----------
  Monthly EPO dose                         500.0      13,800.0      22,100.0   52,000.0   116,000.0   176,400.0   728,000.0
  Monthly EPO dose/patient weight in kg     3.4        180.1         291.4      677.1      1534.8      2346.7     476,666.7
  Resistance index^†^                      34.0        1140.7        1869.2     4442.3    10,361.9    16,252.3    111,815.5

EPO, erythropoietin.

^\*^Monthly erythropoietin dose, monthly erythropoietin dose divided by patient weight in kilograms, and monthly erythropoietin dose divided by patient hemoglobin level.

^†^Monthly EPO dose divided by patient hemoglobin level.

Comorbid conditions assessed during the antecedent period were atherosclerotic heart disease, congestive heart failure (CHF), cerebrovascular accident/transient ischemic attack, peripheral vascular disease (PVD), other cardiac disease, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, dysrhythmia, cancer, and diabetes. These conditions were again assessed during the concurrent period. We also characterized age, sex, race, cause of renal failure, dialysis duration, average body mass index during the concurrent period, vascular access complications, intravenous (IV) antibiotic use, number of hospital admissions, number of hospitalization days, infectious hospitalizations, profit status of dialysis provider, and region of the country. Both antecedent and concurrent comorbid conditions were defined from Medicare Part A and Part B claims, using a method previously validated for diabetes \[[@B1]\]. This method uses International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes, and requires at least one inpatient, home health, or skilled nursing facility claim with a qualifying diagnosis, or at least two physician/supplier or hospital outpatient claims with a qualifying diagnosis, to define the condition.

Analysis
--------

Descriptive statistics for categorical variables (count \[*n*\], percent) were used to examine patient demographic characteristics and comorbid conditions according to hyporesponsiveness definition (total EPO dose, EPO dose/weight in kg, EPO dose/hemoglobin level) and category (chronic, acute, other). Logistic regression was used to assess associations of patient factors with any hyporesponsiveness (chronic, acute, and other). SAS, version 9.1 (SAS Institute Inc., Cary, North Carolina) was used for data analysis.

Ethics statement
----------------

This study was performed with the approval of the Hennepin County Medical Center (Minneapolis, Minnesota) institutional review board.

Results
=======

The study included 138,688 patients. Patient characteristics were similar to the overall Medicare prevalent hemodialysis population: 52% male, 42% African American, 48% aged ≥ 65 years, 45% with diabetes as cause of renal failure, and 42% with dialysis duration \< 3 years.

Table [2](#T2){ref-type="table"} shows the hyporesponsiveness categories obtained using total EPO dose to define monthly hyporesponsiveness, by patient characteristics. The categories are chronic (hyporesponsive for ≥ 4 consecutive months), acute (hyporesponsive for ≤ 3 consecutive months with at least 1 non-hyporesponsive month before and after), and other (some patterns of monthly hyporesponsiveness fit neither the chronic nor the acute categories). Of patients with any hyporesponsiveness, 23%, 26%, and 51% were classified as chronic, acute, or other, respectively. To determine how to classify the "other" group, the squared error for each row of Table [2](#T2){ref-type="table"} was calculated, other compared with chronic, and other compared with acute. The square root of the sum of these values (a measure of distance) confirms that the "other" category is most similar to the acute category (distance = 43.6 for other/chronic, distance = 12.0 for other/acute); therefore, other and acute were grouped into a "non-chronic" category for further analyses. Distance was also assessed using the other 2 definitions of hyporesponsiveness, with similar findings (not shown).

###### 

Hyporesponsiveness categories for total erythropoietin dose

                                                          **Hyporesponsiveness**   **Squared difference**                          
  -------------------------------------------- --------- ------------------------ ------------------------ ------ -------- ------- ------
  *n*                                           138,688          111,422                    6248            7219   13,799             
  **Sex**                                                                                                                             
  Men                                            51.8              51.6                     54.7            51.0    52.5     4.9    2.3
  Women                                          48.2              48.4                     45.3            49.0    47.5              
  **Race**                                                                                                                            
  White                                          51.4              52.6                     46.2            47.4    46.0     0.1    1.8
  African American                               42.2              40.5                     49.8            47.5    49.5     0.1    4.1
  Other                                           6.4              6.9                      3.9             5.1     4.4               
  **Age, years**                                                                                                                      
  \< 40                                           8.1              7.5                      12.9            9.8     10.3     7.0    0.2
  40-64                                          44.3              42.7                     54.9            48.3    50.3    20.6    4.1
  65-74                                          24.9              25.5                     19.8            24.5    22.8     9.3    2.9
  ≥ 75                                           22.7              24.4                     12.5            17.4    16.6              
  **Cause of renal failure**                                                                                                          
  Diabetes                                       44.9              45.3                     38.7            45.7    44.1    29.0    2.8
  Hypertension                                   29.3              29.6                     27.8            27.8    28.8     1.0    1.1
  Glomerulonephritis                             10.2              10.0                     12.2            10.3    10.7     2.2    0.1
  Cystic kidney disease                           2.2              2.2                      2.1             2.0     1.8      0.1    0.1
  Other                                          13.5              13.0                     19.3            14.2    14.7              
  **Dialysis duration, years**                                                                                                        
  \< 1                                            9.6              9.8                      7.7             9.4     8.6      0.9    0.5
  1 to \< 3                                      32.6              33.5                     26.3            31.3    28.9     6.7    5.8
  3 to \< 5                                      23.6              23.6                     23.2            23.0    23.8     0.3    0.7
  ≥ 5                                            34.3              33.1                     42.8            36.4    38.7              
  **Average BMI, kg/m**^**2**^                                                                                                        
  \< 18.5                                         3.7              3.6                      3.3             4.3     3.8      0.2    0.3
  ≥ 18.5 and \< 25                               34.9              35.2                     30.4            36.5    33.5     9.4    8.8
  ≥ 25 and \< 30                                 28.5              28.9                     25.6            27.6    27.3     2.8    0.1
  ≥ 30                                           33.0              32.3                     40.7            31.6    35.4              
  **Antecedent comorbid conditions**                                                                                                  
  ASHD                                           22.0              20.4                     26.0            29.8    28.5     6.3    1.6
  CHF                                            19.6              17.2                     29.9            29.7    28.8     1.3    0.8
  CVA/TIA                                         7.4              6.9                      7.5             10.9    9.6      4.0    1.9
  PVD                                            16.5              14.8                     23.1            24.2    23.3     0.1    0.9
  Other cardiac disease                          12.4              10.6                     20.3            20.0    19.2     1.1    0.6
  COPD                                            8.4              7.3                      13.2            12.7    12.9     0.1    0.0
  GI bleeding                                     3.3              2.5                      7.2             6.1     6.1      1.2    0.0
  Liver disease                                   5.5              5.2                      7.4             6.3     6.8      0.3    0.3
  Dysrhythmia                                    13.7              12.4                     19.1            19.2    18.8     0.0    0.1
  Cancer                                          4.1              3.6                      7.2             5.3     5.8      2.1    0.2
  Diabetes                                       49.7              48.9                     49.2            55.0    53.0    14.1    4.1
  **Concurrent comorbid conditions**                                                                                                  
  ASHD                                           30.1              28.4                     32.9            41.2    37.0    16.8    17.3
  CHF                                            27.6              24.6                     38.9            42.9    39.1     0.0    14.7
  CVA/TIA                                        10.9              10.2                     10.5            16.9    13.5     9.3    11.3
  PVD                                            24.8              22.8                     30.3            35.8    32.7     5.6    10.0
  Other cardiac disease                          19.7              17.2                     28.3            32.4    28.8     0.3    12.5
  COPD                                           12.5              11.1                     18.2            19.2    17.9     0.1    1.6
  GI bleeding                                     5.3              4.1                      10.6            11.2    9.6      1.0    2.7
  Liver disease                                   6.4              6.0                      8.9             7.8     8.0      0.9    0.0
  Dysrhythmia                                    19.8              18.1                     25.1            28.4    26.4     1.8    3.9
  Cancer                                          5.6              5.0                      9.9             7.2     7.6      5.5    0.1
  Diabetes                                       57.3              56.7                     55.6            62.1    60.2    20.8    3.7
  **Number of vascular access complication**                                                                                          
  0                                              61.9              61.9                     64.0            55.4    53.7    106.1   2.7
  1-3                                            19.9              19.9                     19.1            21.7    23.4    17.8    2.7
  ≥ 4                                            18.2              18.2                     16.9            22.9    22.9              
  **Average iron dose per month, mg**                                                                                                 
  Non-users                                      15.1              16.2                     13.0            9.5     10.4     7.1    0.7
  \< 233                                         21.1              23.0                     11.4            14.6    13.9     6.6    0.5
  ≥ 233 and \< 360                               21.1              21.5                     16.6            20.2    20.1    12.0    0.0
  ≥ 360 and \< 460                               20.9              20.5                     20.9            23.9    22.5     2.5    2.0
  ≥ 460                                          21.8              18.8                     38.1            31.8    33.2    24.5    1.9
  **IV antibiotic use**                                                                                                               
  No                                             76.9              76.9                     79.6            65.6    66.6    168.0   1.0
  Yes                                            23.1              23.1                     20.5            34.4    33.4              
  **Number of hospital admissions**                                                                                                   
  0                                              63.3              63.3                     68.3            45.7    44.8    549.0   0.8
  1                                              20.8              20.8                     19.4            26.7    26.0    43.2    0.5
  ≥ 2                                            15.9              15.9                     12.3            27.6    29.2              
  **Number of hospitalization days**                                                                                                  
  0                                              63.3              63.3                     68.3            45.7    44.8    549.0   0.8
  1-7                                            18.4              18.4                     17.3            24.4    22.4    25.6    4.2
  ≥ 8                                            18.4              18.4                     14.4            29.8    32.8              
  **Infectious hospitalizations**                                                                                                     
  No                                             88.2              88.2                     90.6            80.3    79.2    129.8   1.2
  Yes                                            11.8              11.8                     9.4             19.7    20.8              
  **Dialysis provider**                                                                                                               
  Non-profit                                     14.0              14.0                     14.7            12.4    11.0    13.0    1.7
  For profit                                     85.0              85.0                     84.4            86.5    87.6     9.8    1.1
  Unknown                                         1.0              1.0                      0.9             1.1     1.4               
  **Region**                                                                                                                          
  Northeast                                      15.7              15.7                     15.7            15.0    15.1     0.4    0.0
  Midwest                                        19.1              19.1                     19.4            19.0    17.8     2.6    1.5
  South                                          45.2              45.2                     43.7            50.8    51.9    67.9    1.2
  West                                           17.2              17.2                     18.3            12.6    12.6    33.1    0.0
  Unknown                                         2.8              2.8                      2.9             2.7     2.7               
  Distance                                        \--              \--                      \--             \--     \--     43.6    12.0

*ASHD*, atherosclerotic heart disease; *BMI*, body mass index; *CHF*, congestive heart failure; *COPD*, chronic obstructive pulmonary disease; *CVA/TIA*, cerebrovascular accident/transient ischemic attack; *GI*, gastrointestinal; *IV,* intravenous; *PVD*, peripheral vascular disease.

Table [3](#T3){ref-type="table"} shows the three definitions of hyporesponsiveness, and within each the categories of non-hyporesponsive, chronic, and non-chronic. A similar number of patients were classified as non-hyporesponsive, chronic, and non-chronic by each of the three definitions, and a comparison of patient characteristics showed no major differences. Men were more likely than women to be chronically hyporesponsive; African Americans were more likely than whites or members of other races to be hyporesponsive generally (chronic and non-chronic). Younger patients were more likely to be hyporesponsive generally, and patients whose cause of renal failure was other than diabetes or hypertension were more likely to be chronically hyporesponsive. Comparing comorbid conditions, all were somewhat more likely when ascertained concurrently with hyporesponsiveness than when ascertained in the antecedent period. Comorbidity burdens were lowest for non-hyporesponsive patients. Comparing chronic with non-chronic hyporesponsiveness with respect to comorbid conditions, levels of comorbidity were generally slightly higher for patients classified with non-chronic hyporesponsiveness, particularly when comorbidity was assessed concurrently with the hyporesponsive period. Patients receiving IV antibiotics were more likely to be classified with non-chronic hyporesponsiveness, as were patients with three or more hospitalizations.

###### 

The three definitions of hyporesponsiveness

                                                **Monthly EPO dose**   **Monthly EPO dose/patient weight in kg**   **Resistance index**^**\***^                                                                        
  -------------------------------------------- ---------------------- ------------------------------------------- ------------------------------ -------- --------- ------ -------- -------- --------- ------ -------- --------
  *n*                                                 111,422                            6248                                 21,018              27,266   110,767   5905   22,016   27,921   110,022   5761   22,905   28,666
  **Sex**                                                                                                                                                                                                                  
  Men                                                   51.6                             54.7                                  52.0                52.6     52.9     48.3    47.3     47.5     51.6     55.0    51.7     52.4
  Women                                                 48.4                             45.3                                  48.0                47.4     47.1     51.7    52.7     52.5     48.4     45.0    48.3     47.6
  **Race**                                                                                                                                                                                                                 
  White                                                 52.6                             46.2                                  46.5                46.4     52.5     45.8    47.2     46.9     52.6     46.4    46.7     46.6
  African American                                      40.5                             49.8                                  48.8                49.1     40.9     48.4    46.7     47.0     40.5     49.6    48.4     48.6
  Other                                                 6.9                               3.9                                  4.7                 4.5       6.5     5.9     6.2      6.1       6.9     4.0     4.9      4.7
  **Age, years**                                                                                                                                                                                                           
  \< 40                                                 7.5                              12.9                                  10.1                10.7      7.5     13.7    9.8      10.6      7.4     13.3    10.1     10.7
  40 to 64                                              42.7                             54.9                                  49.6                50.8     43.7     49.2    45.8     46.5     42.7     54.8    49.2     50.3
  65 to 74                                              25.5                             19.8                                  23.4                22.6     25.3     20.5    23.8     23.1     25.4     19.4    23.7     22.8
  ≥ 75                                                  24.4                             12.5                                  16.9                15.9     23.5     16.6    20.5     19.7     24.5     12.5    17.0     16.1
  **Cause of renal failure**                                                                                                                                                                                               
  Diabetes                                              45.3                             38.7                                  44.6                43.3     46.3     32.4    41.3     39.4     45.3     38.3    44.5     43.3
  Hypertension                                          29.6                             27.8                                  28.4                28.3     29.2     29.6    29.9     29.8     29.6     27.7    28.5     28.3
  Glomerulonephritis                                    10.0                             12.2                                  10.6                10.9      9.9     13.2    10.8     11.3     10.2     10.0    12.1     10.5
  Cystic kidney disease                                 2.2                               2.1                                  1.9                 1.9       2.2     2.2     2.1      2.1       2.2     2.2     2.1      2.1
  Other                                                 13.0                             19.3                                  14.5                15.6     12.5     22.6    16.0     17.4     13.5     12.9    19.8     14.4
  **Dialysis duration, years**                                                                                                                                                                                             
  \< 1                                                  9.8                               7.7                                  8.9                 8.6       9.8     7.5     8.8      8.5       9.8     7.9     8.9      8.7
  1 to \< 3                                             33.5                             26.3                                  29.7                29.0     33.9     24.2    28.6     27.7     33.5     26.4    30.0     29.3
  3 to \< 5                                             23.6                             23.2                                  23.5                23.4     23.8     21.2    23.1     22.7     23.6     22.9    23.5     23.4
  ≥ 5                                                   33.1                             42.8                                  37.9                39.0     32.5     47.0    39.5     41.1     33.1     42.9    37.5     38.6
  **Average BMI, kg/m**^**2**^                                                                                                                                                                                             
  \< 18.5                                               3.6                               3.3                                  4.0                 3.8       2.8     8.3     6.9      7.2       3.6     3.5     4.1      4.0
  ≥ 18.5 and \< 25                                      35.2                             30.4                                  34.5                33.6     32.2     47.2    44.7     45.2     35.1     31.1    34.8     34.1
  ≥ 25 and \< 30                                        28.9                             25.6                                  27.4                27.0     29.2     25.1    26.2     26.0     28.9     25.9    27.2     26.9
  ≥ 30                                                  32.3                             40.7                                  34.1                35.6     35.8     19.4    22.1     21.5     32.4     39.5    33.9     35.0
  **Antecedent comorbid conditions**                                                                                                                                                                                       
  ASHD                                                  20.4                             26.0                                  29.0                28.3     20.3     26.8    29.1     28.6     20.3     25.9    28.7     28.1
  CHF                                                   17.2                             29.9                                  29.1                29.3     17.0     30.7    29.6     29.8     17.1     29.9    28.8     29.0
  CVA/TIA                                               6.9                               7.5                                  10.0                9.5       6.7     8.7     10.5     10.1      6.9     7.6     9.9      9.4
  PVD                                                   14.8                             23.1                                  23.6                23.5     14.9     22.7    23.3     23.2     14.8     23.4    23.3     23.3
  Other cardiac disease                                 10.6                             20.3                                  19.5                19.7     10.4     21.8    20.0     20.4     10.6     20.4    19.0     19.3
  COPD                                                  7.3                              13.2                                  12.8                12.9      7.2     13.6    12.9     13.0      7.3     13.4    12.6     12.8
  GI bleeding                                           2.5                               7.2                                  6.1                 6.4       2.4     8.0     6.4      6.7       2.5     7.6     6.1      6.4
  Liver disease                                         5.2                               7.4                                  6.6                 6.8       5.2     7.7     6.5      6.8       5.2     7.6     6.6      6.8
  Dysrhythmia                                           12.4                             19.1                                  19.0                19.0     12.2     20.0    19.1     19.3     12.4     19.3    18.6     18.7
  Cancer                                                3.6                               7.2                                  5.6                 6.0       3.5     8.0     5.6      6.1       3.6     7.6     5.5      5.9
  Diabetes                                              48.9                             49.2                                  53.6                52.6     49.8     43.6    50.4     49.0     48.9     49.3    53.6     52.7
  **Concurrent comorbid conditions**                                                                                                                                                                                       
  ASHD                                                  28.4                             32.9                                  38.4                37.2     28.3     33.6    38.4     37.4     28.3     33.2    38.4     37.3
  CHF                                                   24.6                             38.9                                  40.4                40.1     24.3     40.2    40.9     40.7     24.4     39.9    40.0     40.0
  CVA/TIA                                               10.2                             10.5                                  14.6                13.7      9.9     11.9    15.5     14.7     10.1     10.7    14.6     13.8
  PVD                                                   22.8                             30.3                                  33.7                32.9     22.8     30.5    33.6     32.9     22.6     31.1    33.7     33.2
  Other cardiac disease                                 17.2                             28.3                                  30.0                29.6     16.9     30.9    30.6     30.7     17.0     29.2    29.9     29.8
  COPD                                                  11.1                             18.2                                  18.4                18.3     11.0     18.1    18.5     18.4     11.0     19.1    18.2     18.4
  GI bleeding                                           4.1                              10.6                                  10.1                10.2      4.0     11.9    10.2     10.6      4.0     11.4    10.2     10.4
  Liver disease                                         6.0                               8.9                                  7.9                 8.1       5.9     9.4     7.9      8.2       6.0     9.3     7.7      8.0
  Dysrhythmia                                           18.1                             25.1                                  27.1                26.6     18.0     26.8    27.1     27.0     18.0     25.8    26.8     26.6
  Cancer                                                5.0                               9.9                                  7.4                 8.0       4.9     10.6    7.8      8.4       5.0     10.5    7.4      8.0
  Diabetes                                              56.7                             55.6                                  60.8                59.6     57.7     49.3    57.5     55.8     56.6     55.5    60.8     59.7
  **Number of vascular access complication**                                                                                                                                                                               
  0                                                     61.9                             64.0                                  53.0                55.5     63.7     56.1    54.5     54.8     64.2     55.1    53.0     53.4
  1-3                                                   19.9                             19.1                                  23.3                22.4     19.2     21.9    22.7     22.5     19.1     21.8    23.2     22.9
  ≥ 4                                                   18.2                             16.9                                  23.7                22.1     17.0     22.0    22.9     22.7     16.7     23.1    23.8     23.7
  **Average iron dose per month, mg**                                                                                                                                                                                      
  Non-users                                             16.2                             13.0                                  10.1                10.7     16.0     14.2    11.1     11.8     16.2     13.5    10.4     11.0
  \< 233                                                23.0                             11.4                                  14.2                13.5     22.9     12.4    14.9     14.3     23.1     11.4    14.4     13.8
  ≥ 233 and \< 360                                      21.5                             16.6                                  20.1                19.3     21.5     17.1    20.2     19.5     21.5     16.4    20.3     19.5
  ≥ 360 and \< 460                                      20.5                             20.9                                  22.9                22.5     20.6     20.7    22.3     21.9     20.6     20.4    22.5     22.1
  ≥ 460                                                 18.8                             38.1                                  32.7                34.0     19.1     35.5    31.6     32.4     18.7     38.3    32.4     33.6
  **IV antibiotic use**                                                                                                                                                                                                    
  No                                                    76.9                             79.6                                  66.5                69.5     79.4     66.3    67.5     67.2     79.7     64.9    66.5     66.2
  Yes                                                   23.1                             20.5                                  33.5                30.5     20.6     33.7    32.5     32.8     20.3     35.1    33.5     33.8
  **Number of hospital admissions**                                                                                                                                                                                        
  0                                                     63.3                             68.3                                  42.1                48.1     68.6     43.6    42.0     42.3     68.7     43.5    42.2     42.5
  1                                                     20.8                             19.4                                  26.4                24.8     19.4     26.2    26.7     26.6     19.3     26.7    26.7     26.7
  ≥ 2                                                   15.9                             12.3                                  31.5                27.1     12.1     30.2    31.4     31.1     12.0     29.8    31.2     30.9
  **Number of hospitalization days**                                                                                                                                                                                       
  0                                                     63.3                             68.3                                  42.1                48.1     68.6     43.6    42.0     42.3     68.7     43.5    42.2     42.5
  1-7                                                   18.4                             17.3                                  22.1                21.0     17.3     23.8    22.2     22.5     17.2     24.1    22.4     22.7
  ≥ 8                                                   18.4                             14.4                                  35.8                30.9     14.1     32.6    35.8     35.1     14.1     32.4    35.4     34.8
  **Infectious hospitalizations**                                                                                                                                                                                          
  No                                                    88.2                             90.6                                  78.0                80.9     90.7     79.1    78.2     78.4     90.8     78.9    78.3     78.4
  Yes                                                   11.8                              9.4                                  22.0                19.1      9.3     20.9    21.8     21.6      9.2     21.1    21.7     21.6
  **Dialysis provider**                                                                                                                                                                                                    
  Non-profit                                            14.0                             14.7                                  11.2                12.0     14.6     13.0    11.6     11.9     14.6     12.5    11.7     11.9
  For profit                                            85.0                             84.4                                  87.5                86.8     84.5     85.8    87.1     86.8     84.5     86.4    87.0     86.9
  Unknown                                               1.0                               0.9                                  1.3                 1.2       0.9     1.2     1.3      1.3       0.9     1.2     1.3      1.3
  **Region**                                                                                                                                                                                                               
  Northeast                                             15.7                             15.7                                  15.4                15.5     15.6     15.6    15.9     15.8     15.8     15.3    15.3     15.3
  Midwest                                               19.1                             19.4                                  17.5                17.9     19.5     17.5    17.2     17.3     19.4     19.0    17.8     18.0
  South                                                 45.2                             43.7                                  51.7                49.8     44.0     49.4    50.3     50.1     43.7     50.2    51.4     51.2
  West                                                  17.2                             18.3                                  12.9                14.2     18.0     14.8    14.1     14.2     18.3     12.9    13.1     13.1
  Unknown                                               2.8                               2.9                                  2.5                 2.6       2.9     2.9     2.4      2.5       2.9     2.6     2.5      2.5

*ASHD*, atherosclerotic heart disease; *BMI*, body mass index; *CHF*, congestive heart failure; *COPD*, chronic obstructive pulmonary disease; *CVA/TIA*, cerebrovascular accident/transient ischemic attack; *EPO*, erythropoietin; *GI*, gastrointestinal; *IV*, intravenous; *PVD*, peripheral vascular disease.
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Table [4](#T4){ref-type="table"} shows adjusted odds ratios for any hyporesponsiveness compared with none. Two of the three methods showed similar results: total EPO dose and EPO dose divided by hemoglobin level (resistance index). Women, African Americans, and patients aged \< 40 years, with cause of renal failure other than diabetes or hypertension, or longer dialysis duration, were more likely to be hyporesponsive. The antecedent comorbid conditions most predictive of any subsequent hyporesponsiveness were CHF, PVD, other cardiac disease, gastrointestinal bleeding, and cancer. Of concurrent comorbid conditions, associations with any hyporesponsiveness were strongest for gastrointestinal bleeding and cancer. Results of EPO dose per kg of body weight were somewhat different with respect to odds ratios for weight and sex; this is not surprising, since in this model, weight would be expected to be a strong predictor of EPO dose divided by weight. The term for sex is also affected since weight is correlated with sex.

###### 

Adjusted odds ratios for hyporesponsiveness

                                                **Monthly EPO dose**   **Monthly EPO dose/patient weight in kg**   **Resistance index**^**\***^                                 
  -------------------------------------------- ---------------------- ------------------------------------------- ------------------------------ ----------- ------------------ -----------
  **Sex**                                                                                                                                                                             
  Men                                                   1.00                                                                   1.00                                 1.00              
  Women                                           1.08 (1.04-1.11)                     \< 0.0001                         1.49 (1.44-1.54)         \< 0.0001   1.08 (1.05-1.11)   \< 0.0001
  **Race**                                                                                                                                                                            
  White                                                 1.00                                                                   1.00                                 1.00              
  African American                                1.11 (1.07-1.15)                     \< 0.0001                         1.07 (1.03-1.11)         \< 0.0001   1.10 (1.06-1.14)   \< 0.0001
  Other                                           1.01 (0.94-1.08)                       0.89                            1.22 (1.15-1.30)         \< 0.0001   1.04 (0.97-1.12)     0.23
  **Age- years**                                                                                                                                                                      
  \< 40                                                 1.00                                                                   1.00                                 1.00              
  40 to 64                                        0.87 (0.82-0.92)                     \< 0.0001                         0.85 (0.81-0.90)         \< 0.0001   0.86 (0.81-0.91)   \< 0.0001
  65 to 74                                        0.68 (0.64-0.73)                     \< 0.0001                         0.73 (0.68-0.77)         \< 0.0001   0.69 (0.65-0.73)   \< 0.0001
  ≥ 75                                            0.54 (0.51-0.58)                     \< 0.0001                         0.61 (0.57-0.65)         \< 0.0001   0.54 (0.51-0.57)   \< 0.0001
  **Cause of renal failure**                                                                                                                                                          
  Diabetes                                              1.00                                                                   1.00                                 1.00             s
  Hypertension                                    1.11 (1.06-1.16)                     \< 0.0001                         1.12 (1.07-1.17)         \< 0.0001   1.12 (1.07-1.17)   \< 0.0001
  Glomerulonephritis                              1.20 (1.13-1.28)                     \< 0.0001                         1.18 (1.11-1.25)         \< 0.0001   1.22 (1.15-1.30)   \< 0.0001
  Cystic kidney disease                           1.05 (0.94-1.18)                      0.3771                           1.03 (0.93-1.15)          0.5768     1.07 (0.96-1.20)    0.2223
  Other                                           1.40 (1.32-1.47)                     \< 0.0001                         1.44 (1.36-1.52)         \< 0.0001   1.40 (1.33-1.48)   \< 0.0001
  **Dialysis duration- years**                                                                                                                                                        
  \< 1                                                  1.00                                                                   1.00                                 1.00              
  1 to \< 3                                       1.13 (1.06-1.19)                     \< 0.0001                         1.05 (0.99-1.11)           0.10      1.13 (1.07-1.19)   \< 0.0001
  3 to \< 5                                       1.36 (1.29-1.45)                     \< 0.0001                         1.28 (1.21-1.36)         \< 0.0001   1.34 (1.27-1.42)   \< 0.0001
  ≥ 5                                             1.60 (1.51-1.70)                     \< 0.0001                         1.57 (1.48-1.66)         \< 0.0001   1.56 (1.47-1.65)   \< 0.0001
  **Average BMI- kg/m**^**2**^                                                                                                                                                        
  \< 18.5                                               1.00                                                                   1.00                                 1.00              
  ≥ 18.5 and \< 25                                0.97 (0.90-1.05)                       0.48                            0.56 (0.52-0.60)         \< 0.0001   0.94 (0.87-1.02)     0.12
  ≥ 25 and \< 30                                  0.99 (0.91-1.07)                       0.73                            0.35 (0.32-0.37)         \< 0.0001   0.94 (0.86-1.02)     0.12
  ≥ 30                                            1.05 (0.97-1.14)                       0.23                            0.20 (0.18-0.21)         \< 0.0001   0.99 (0.91-1.07)     0.79
  **Antecedent comorbid conditions**                                                                                                                                                  
  ASHD                                            1.08 (1.04-1.13)                      0.0002                           1.11 (1.06-1.15)         \< 0.0001   1.08 (1.04-1.13)    0.0002
  CHF                                             1.23 (1.18-1.28)                     \< 0.0001                         1.24 (1.19-1.29)         \< 0.0001   1.24 (1.19-1.29)   \< 0.0001
  CVA/TIA                                         1.05 (0.99-1.11)                       0.09                            1.07 (1.01-1.13)           0.02      1.05 (0.99-1.11)     0.12
  PVD                                             1.25 (1.20-1.30)                     \< 0.0001                         1.21 (1.17-1.26)         \< 0.0001   1.24 (1.19-1.29)   \< 0.0001
  Other cardiac disease                           1.25 (1.20-1.31)                     \< 0.0001                         1.27 (1.21-1.32)         \< 0.0001   1.21 (1.16-1.26)   \< 0.0001
  COPD                                            1.18 (1.12-1.25)                     \< 0.0001                         1.16 (1.10-1.23)         \< 0.0001   1.16 (1.10-1.23)   \< 0.0001
  GI bleeding                                     1.51 (1.40-1.62)                     \< 0.0001                         1.62 (1.51-1.74)         \< 0.0001   1.56 (1.45-1.68)   \< 0.0001
  Liver disease                                   1.17 (1.07-1.28)                       0.00                            1.13 (1.04-1.24)           0.01      1.19 (1.09-1.30)   \< 0.0001
  Dysrhythmia                                     1.16 (1.10-1.21)                     \< 0.0001                         1.15 (1.09-1.20)         \< 0.0001   1.14 (1.09-1.19)   \< 0.0001
  Cancer                                          1.45 (1.33-1.57)                     \< 0.0001                         1.36 (1.26-1.48)         \< 0.0001   1.43 (1.32-1.55)   \< 0.0001
  Diabetes                                        1.07 (1.02-1.13)                       0.00                            1.06 (1.01-1.11)           0.02      1.09 (1.04-1.14)     0.00
  **Concurrent comorbid conditions**                                                                                                                                                  
  ASHD                                            0.94 (0.90-0.97)                       0.00                            0.93 (0.90-0.97)           0.00      0.94 (0.90-0.97)     0.00
  CHF                                             1.12 (1.08-1.17)                     \< 0.0001                         1.14 (1.09-1.18)         \< 0.0001   1.10 (1.06-1.15)   \< 0.0001
  CVA/TIA                                         0.94 (0.90-0.99)                       0.02                            0.99 (0.94-1.04)           0.59      0.94 (0.89-0.99)     0.01
  PVD                                             1.02 (0.98-1.06)                       0.25                            1.03 (1.00-1.07)           0.08      1.03 (1.00-1.07)     0.09
  Other cardiac disease                           1.14 (1.10-1.18)                     \< 0.0001                         1.16 (1.12-1.20)         \< 0.0001   1.15 (1.10-1.19)   \< 0.0001
  COPD                                            1.04 (0.99-1.09)                       0.15                            1.01 (0.96-1.06)           0.63      1.04 (1.00-1.09)     0.08
  GI bleeding                                     1.45 (1.36-1.53)                     \< 0.0001                         1.44 (1.35-1.52)         \< 0.0001   1.50 (1.41-1.59)   \< 0.0001
  Liver disease                                   1.05 (0.97-1.14)                       0.24                            1.09 (1.01-1.19)           0.03      1.01 (0.93-1.09)     0.86
  Dysrhythmia                                     1.03 (0.98-1.07)                       0.21                            1.00 (0.96-1.04)           0.87      1.02 (0.98-1.07)     0.31
  Cancer                                          1.32 (1.23-1.42)                     \< 0.0001                         1.36 (1.27-1.47)         \< 0.0001   1.32 (1.23-1.41)   \< 0.0001
  Diabetes                                        1.02 (0.97-1.07)                       0.38                            0.98 (0.93-1.03)           0.39      1.02 (0.98-1.07)     0.35
  **Number of vascular access complication**                                                                                                                                          
  0                                                     1.00                                                                   1.00                                 1.00              
  1-3                                             1.10 (1.06-1.15)                     \< 0.0001                         1.07 (1.03-1.11)          0.0005     1.10 (1.06-1.14)   \< 0.0001
  ≥ 4                                             1.15 (1.10-1.20)                     \< 0.0001                         1.13 (1.08-1.17)         \< 0.0001   1.16 (1.11-1.21)   \< 0.0001
  **Average iron dose per month- mg**                                                                                                                                                 
  Non-users                                             1.00                                                                   1.00                                 1.00              
  \< 233                                          1.00 (0.94-1.06)                      0.9360                           0.97 (0.92-1.03)          0.3598     0.97 (0.91-1.02)    0.2483
  ≥ 233 and \< 360                                1.31 (1.23-1.38)                     \< 0.0001                         1.25 (1.18-1.32)         \< 0.0001   1.28 (1.21-1.35)   \< 0.0001
  ≥ 360 and \< 460                                1.55 (1.47-1.64)                     \< 0.0001                         1.45 (1.38-1.53)         \< 0.0001   1.48 (1.40-1.56)   \< 0.0001
  ≥ 460                                           2.36 (2.24-2.50)                     \< 0.0001                         2.19 (2.07-2.31)         \< 0.0001   2.27 (2.15-2.39)   \< 0.0001
  **IV antibiotic use**                                                                                                                                                               
  No                                                    1.00                                                                   1.00                                 1.00              
  Yes                                             1.26 (1.22-1.31)                     \< 0.0001                         1.26 (1.22-1.31)         \< 0.0001   1.26 (1.22-1.31)   \< 0.0001
  **Number of hospital admissions**                                                                                                                                                   
  0                                                     1.00                                                                   1.00                                 1.00              
  1                                               1.49 (1.43-1.56)                     \< 0.0001                         1.51 (1.45-1.58)         \< 0.0001   1.54 (1.48-1.60)   \< 0.0001
  ≥ 2                                             1.88 (1.77-1.98)                     \< 0.0001                         1.91 (1.81-2.02)         \< 0.0001   1.95 (1.84-2.06)   \< 0.0001
  **Infectious hospitalizations**                                                                                                                                                     
  No                                                    1.00                                                                   1.00                                 1.00              
  Yes                                             1.10 (1.05-1.15)                     \< 0.0001                         1.13 (1.08-1.18)         \< 0.0001   1.10 (1.05-1.15)   \< 0.0001
  **Dialysis provider**                                                                                                                                                               
  Non-profit                                            1.00                                                                   1.00                                 1.00              
  For profit                                      1.19 (1.10-1.28)                     \< 0.0001                         1.19 (1.10-1.28)         \< 0.0001   1.18 (1.09-1.27)   \< 0.0001
  Unknown                                         1.56 (1.33-1.83)                     \< 0.0001                         1.57 (1.34-1.85)         \< 0.0001   1.49 (1.27-1.75)   \< 0.0001
  **Region**                                                                                                                                                                          
  Northeast                                             1.00                                                                   1.00                                 1.00              
  Midwest                                         0.89 (0.85-0.94)                     \< 0.0001                         0.88 (0.84-0.93)         \< 0.0001   0.92 (0.87-0.97)    0.0013
  South                                           1.16 (1.11-1.21)                     \< 0.0001                         1.14 (1.09-1.19)         \< 0.0001   1.17 (1.12-1.23)   \< 0.0001
  West                                            0.80 (0.75-0.84)                     \< 0.0001                         0.83 (0.79-0.88)         \< 0.0001   0.81 (0.77-0.86)   \< 0.0001
  Unknown                                         0.91 (0.82-1.00)                      0.0576                           0.90 (0.82-1.00)          0.0401     0.88 (0.80-0.97)    0.0116

*ASHD*, atherosclerotic heart disease; *BMI*, body mass index; *CHF*, congestive heart failure; *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *CVA/TIA*, cerebrovascular accident/transient ischemic attack; *EPO*, erythropoietin; *GI*, gastrointestinal; *IV*, intravenous; *PVD*, peripheral vascular disease.
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Discussion
==========

We found very similar associations between patient characteristics and three methods of characterizing EPO hyporesponsiveness (total EPO dose, EPO dose per kg of body weight, or EPO dose per hemoglobin level). Given this finding, using the simplest of the three methods we investigated, total EPO dose, to characterize hyporesponsiveness seems justifiable. Our findings relating hyporesponsiveness to patient characteristics are largely in agreement with other studies in other populations that used different methods to characterize hyporesponsiveness. With respect to the proportion of patients classified as hyporesponsive, our definitions produced approximately 20%, 4.5%, and 15% of patients with any, chronic, and non-chronic hyporesponsiveness, respectively. Other studies have not separated chronic from non-chronic hyporesponsiveness. Attalah et al \[[@B2]\] found that 17.6% of patients were hyporesponsive, defined as requiring \> 450 U/kg/week IV EPO, with average 3-month hemoglobin \< 11 g/dL, ferritin ≥ 500 ng/mL, and TSAT ≤ 50%. Johnson et al \[[@B3]\] describe approximately 5% to 10% of patients as hyporesponsive, defined as requiring \> 450 U/kg/week IV EPO.

Potential causes of hyporesponsiveness have been previously investigated and described, with varying levels of supporting evidence \[[@B3]-[@B9]\]. Causes include absolute or functional iron deficiency, inflammation, infection, lack of dialysis adequacy, hyperparathyroidism, hemolysis, nutritional factor deficiencies, aluminum overload, pure red cell aplasia, malignancy, bone marrow disorders, myelosuppressive agent use, and use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

Using data from a large dialysis organization, Kalantar-Zadeh et al \[[@B10]\] examined predictors of hyporesponsiveness. Although they used a measure of hyporesponsiveness different from ours (fitting hemoglobin trajectories to individuals with mixed models), and their primary focus was on iron markers and osteodystrophy, their findings were similar with respect to age, sex, race, and major comorbid conditions, including cancer, CHF, and diabetes. One notable difference was with respect to dialysis duration; we found increasing hyporesponsiveness with longer dialysis duration, compared with their findings of decreased hyporesponsiveness. This may be due to the particular categorization of dialysis duration analyzed. The first 6 months after dialysis initiation, and in particular, the first 3 months, is a period of high risk. The mortality hazard appears to be highest shortly after initiation, and decreases during the first 6 months. Correspondingly, dialysis duration beyond 5 years shows further increasing risk, as patients continue to accumulate comorbidity. Therefore, investigation of hyporesponsiveness associations within the first year, and beyond 5 years, may be important for further study.

In another study by Kalantar-Zadeh et al \[[@B11]\], the authors found associations between inflammatory markers and hyporesponsiveness. We did not have access to data on inflammatory markers; however, our findings of higher comorbidity burden, higher number of vascular access complications, and IV antibiotic use are in general agreement with the earlier findings, since inflammatory burden generally increases with these factors.

Limitations of the current study include lack of laboratory data; somewhat arbitrary definitions of hyporesponsiveness based on the ninetieth percentile of total monthly EPO dose, dose/kg, or dose/hemoglobin level; possible misclassification of comorbid conditions due to use of claims to identify them; lack of data on catheter use, which is known to be associated with increased risk of infection and inflammation; and residual confounding, which may explain some of the adjusted logistic regression findings. With respect to laboratory data, some definitions of hyporesponsiveness in the literature have included information on ferritin and TSAT; these data were not available in our study. Despite these unavailable data, our findings are generally similar to findings of other studies. Another limitation is that knowledge of the distribution of hemoglobin levels in a similar, large population is needed to define a ninetieth percentile. Simply examining the distribution in a small population (for example, at a particular dialysis facility) to find the appropriate cut point, which may not include any hyporesponsive individuals, would not be appropriate.

A potential limitation involves the 2008 timeframe of the data. This period is after release of CHOIR \[[@B12]\] and CREATE \[[@B13]\] study results, which produced a change in ESA dosing and hemoglobin levels, and before implementation of the Medicare reimbursement bundle, which may cause further declines in ESA doses and hemoglobin levels. However, use of the ninetieth percentile cut would still identify patients receiving the highest 10% of doses, given the overall population dosing levels at a point in time.

Conclusions
===========

Associations were similar between patient characteristics/comorbidity and three methods of characterizing EPO hyporesponsiveness. Results using the simplest of the three methods (ninetieth percentile of EPO dose) were also largely similar to other studies, suggesting the utility of the simple method for characterizing hyporesponsiveness. With implementation of the Medicare dialysis reimbursement bundle in January 2011, which includes all injectables, the previous financial incentive to use higher doses of ESAs will be reversed. Anemia management strategies regarding the relative use of ESAs and IV iron therapy may change as a result of this, and how it will affect ESA hyporesponsiveness is unknown. Future studies should continue to investigate this area as anemia management changes in response to the bundle.
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